Endo Pharmaceuticals (ENDP) Announces Resignation of CFO
More News related to ENDP
- Endo Announces Resignation of Board Member
- Endo Pharmaceuticals (ENDP) Accepts UBS's Settlement Offer Related to Auction Rate Securities
- Endo Pharmaceuticals Announces Acceptance of UBS AG Settlement Offer Relating to Auction Rate Securities
- Caris Upgrades Endo Pharmaceuticals (ENDP) to Buy
- Endo Pharmaceuticals (ENDP) Reports Q3 EPS of $0.64, Beats by 12c
More News related to Management Changes
- After-Hours Movers 12/01: Palm (PALM), Mosaic (MOS) Lower on Guidance
- Trading Radar for 12/02: Staples (SPLS), Marvell (MRVL), Solarfun (SOLF), Beazer (BZH), Sears (SHLD) Report; Auto/Truck Sales for Nov. Due
- Unusual 11 Mid-Day Movers 12/01: MNT, PSUN, ALD, PGI Higher; PPC, MTL, EXM, LIZ Lower
- Notable Analyst Rating Changes 12/01: PRU, TOL, DO, WLP Upgraded; SNP, LTD, COG, ADM Downgraded
- Notable Mergers and Acquisitions of the Day 12/01: JNJ/MNT, AIG, F, FFH
Endo Pharmaceuticals (NASDAQ: ENDP) announced today that executive vice president and chief financial officer, Charles A. Rowland, Jr., has resigned effective immediately, to pursue other interests.
Endo Pharmaceuticals has engaged an executive search firm to assist in the search for a new chief financial officer.
Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain.[SM]
Related Categories
Management ChangesStocks Mentioned
-1.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
